As part of our series focussing on medicines available in Australia, we have added a product review of the use of nivolumab, in combination with ipilimumab, in patients with intermediate-/poor-risk, previously untreated, advanced clear cell renal cell carcinoma.
This review discusses indications and dosage, contraindications and a series of clinical studies featuring nivolumab. It provides commentary from Dr Lewis Au, a medical oncologist at the Peter MacCallum Cancer Centre, Melbourne.
Please login below to download this issue (PDF)